Form 4: Bain Capital Life Sciences Entities Adjust Olema Pharmaceuticals Holdings Through Stock Exchange and Warrant Acquisition

Bain Capital Life Sciences Opportunities IV, L.P. exchanged 3,500,000 shares of Olema Pharmaceuticals common stock for a pre-funded warrant to purchase the same number of shares, while also purchasing 300,000 shares at an average price of $5.7579.

Summary

• Bain Capital Life Sciences Opportunities IV, L.P. (BCLS Opportunities IV) engaged in transactions involving Olema Pharmaceuticals, Inc. (OLMA) common stock.
• On January 8, 2025, BCLS Opportunities IV purchased 300,000 shares of common stock at a weighted average price of $5.7579, with individual prices ranging from $5.44 to $5.92.
• On January 10, 2025, BCLS Opportunities IV exchanged 3,500,000 shares of common stock for a pre-funded warrant to purchase 3,500,000 shares of common stock.
• The exchange was executed under Section 3(a)(9) of the Securities Act of 1933.
• The pre-funded warrant does not expire but cannot be exercised if the Bain Capital Life Sciences Entities would own more than 9.99% of Olema's outstanding common stock after the exercise.

Sentiment

Score: 5

Explanation: The document describes routine transactions related to stock ownership and warrant exchanges, with no clear positive or negative implications. It's a neutral reporting of facts.

Risks

• The pre-funded warrant includes a clause preventing exercise if it would result in the Bain Capital Life Sciences Entities owning more than 9.99% of Olema's outstanding shares, which could limit their potential upside.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and significant shareholders, providing transparency to the market.

Stakeholder Impact

• The transactions may influence the market's perception of Olema Pharmaceuticals, potentially affecting shareholder value.

Key Dates